@article{oai:repo.qst.go.jp:00048373,
 author = {Karube, Masataka and Yamamoto, Naoyoshi and Tsuji, Hiroshi and Kanematsu, Nobuyuki and Nakajima, Mio and H, Yamashita and Nakagawa, K and Kamada, Tadashi and 軽部 雅崇 and 山本 直敬 and 辻 比呂志 and 兼松 伸幸 and 中嶋 美緒 and 鎌田 正},
 issue = {1},
 journal = {Radiotherapy and Oncology},
 month = {Aug},
 note = {PURPOSE: 
\nTo investigate carbon-ion radiotherapy (CIRT) for in-field recurrence of stage I non-small cell lung cancer (NSCLC) initially treated with CIRT.
\nMATERIALS AND METHODS: 
\nFrom January 2007 to March 2014, patients initially treated for stage I NSCLC with CIRT and relapsed in-field were candidates. Overall survival (OS) rate, local control (LC) rate, progressive free survival (PFS) rate, dose to the lungs and skin, and adverse effects were analyzed.
\nRESULTS: 
\nTwenty-nine patients were eligible. Median age at re-irradiation was 74years (range 53-90). Median observation period from the first day of re-irradiation was 29months (4-88months). Median prescribed dose was 46.0Gy (RBE) as initial treatment and 66.0Gy (RBE) in 12 fractions as re-irradiation. Two-year OS, LC, and PFS rates after re-irradiation were 69.0% (95% CI: 50.3-83.0), 66.9% (95% CI: 47.5-81.9), and 51.7% (95% CI: 34.1-68.9). Median skin maximum dose was 53.8Gy (RBE) (range 4.4-103.1) and median of mean lung dose was 7.3Gy (RBE) (range 2.6-14.0). There were no severer than grade 2 adverse effects except one (3.4%) grade 3 bacterial pneumonia, which was not considered radiation-induced.
\nCONCLUSION: 
\nCIRT for stage I NSCLC local recurrence is an acceptable definitive re-treatment.},
 pages = {31--35},
 title = {Carbon-ion re-irradiation for recurrences after initial treatment of stage I non-small cell lung cancer with carbon-ion radiotherapy.},
 volume = {125},
 year = {2017}
}